WuXi XDC Recognized as Best CDMO and Best CRO for Consecutive Years
WuXi XDC has been awarded "Best CDMO" for the fourth consecutive year and "Best CRO" for the second consecutive year at the 2026 World ADC Awards.
SHANGHAI AND SAN DIEGO – WuXi XDC Cayman Inc. has received dual recognition at the prominent 2026 World ADC Awards, securing the "Best CDMO" award for the fourth year in a row and the "Best CRO" award for the second consecutive year. These honors highlight WuXi XDC's established position as a global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in the bioconjugate industry.
The awards were presented at the 2026 World ADC Conference, an event that convenes global experts to discuss the full lifecycle of antibody-drug conjugates (ADCs) and other bioconjugates. WuXi XDC was the sole CRDMO to claim both distinctions for two consecutive years.
WuXi XDC provides services spanning from antibody discovery and preclinical candidate development through to clinical and commercial stages. The company reported enabling clients to submit over 160 Investigational New Drug (IND) applications and manage 328 iCMC projects, with 51 new projects initiated in the first half of 2026. The organization employs over 3,600 professionals worldwide.
The company operates a global network of facilities, with its first overseas manufacturing site in Singapore achieving GMP release in August 2026. WuXi XDC has developed a technology portfolio encompassing various conjugation technologies, alongside proprietary linker and payload technologies.